investorscraft@gmail.com

Intrinsic value of AngioDynamics, Inc. (ANGO)

Previous Close$23.78
Intrinsic Value
Upside potential
Previous Close
$23.78

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh10.64 

The original valuation is based on fiscal year data as of 2021-05-31 and quarterly data as of 2022-02-28.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %10.2NaN
Revenue, $291NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m326NaN
Operating income, $m-35NaN
EBITDA, $m-7NaN
Interest expense (income), $mNaN
Earnings before tax, $m-36NaN
Tax expense, $m-5NaN
Net income, $m-32NaN

BALANCE SHEET

Cash and short-term investments, $m48NaN
Total assets, $m561NaN
Adjusted assets (=assets-cash), $m513NaN
Average production assets, $m426NaN
Working capital, $m83NaN
Total debt, $m30NaN
Total liabilities, $m122NaN
Total equity, $m439NaN
Debt-to-equity ratio0.068NaN
Adjusted equity ratio0.767NaN

CASH FLOW

Net income, $m-32NaN
Depreciation, amort., depletion, $m28NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m24NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-5NaN
Free cash flow, $m29NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m83
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount